Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.: PROVE2: Telaprevir with PEG-IFN and RBV in HCV by Hézode, Christophe et al.
Telaprevir and peginterferon with or without ribavirin
for chronic HCV infection.
Christophe He´zode, Nicole Forestier, Geoffrey Dusheiko, Peter Ferenci,
Stanislas Pol, Tobias Goeser, Jean-Pierre Bronowicki, Marc Bourlie`re, Shahin
Gharakhanian, Leif Bengtsson, et al.
To cite this version:
Christophe He´zode, Nicole Forestier, Geoffrey Dusheiko, Peter Ferenci, Stanislas Pol, et al..
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.: PROVE2:
Telaprevir with PEG-IFN and RBV in HCV. The New England Journal of Medicine, 2009, 360
(18), pp.1839-50. <10.1056/NEJMoa0807650>. <inserm-00385235>
HAL Id: inserm-00385235
http://www.hal.inserm.fr/inserm-00385235
Submitted on 18 May 2009
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 360;18 nejm.org april 30, 2009 1839
original article
Telaprevir and Peginterferon with or without 
Ribavirin for Chronic HCV Infection
Christophe Hézode, M.D., Nicole Forestier, M.D., Geoffrey Dusheiko, M.D.,  
Peter Ferenci, M.D., Stanislas Pol, M.D., Tobias Goeser, M.D.,  
Jean-Pierre Bronowicki, M.D., Marc Bourlière, M.D., Shahin Gharakhanian, M.D., 
Leif Bengtsson, B.S.C., Lindsay McNair, M.D., M.P.H., Shelley George, M.D., 
Tara Kieffer, Ph.D., Ann Kwong, Ph.D., Robert S. Kauffman, M.D., Ph.D.,  
John Alam, M.D., Jean-Michel Pawlotsky, M.D., Ph.D., and Stefan Zeuzem, M.D., 
for the PROVE2 Study Team*
From Assistance Publique–Hôpitaux de 
Paris, Henri Mondor Hospital, University 
of Paris 12 and INSERM Unité 955, Cré-
teil (C.H., J.-M.P.); Université Paris Des-
cartes, INSERM Unité 567, and Assistance 
Publique–Hôpitaux de Paris, Cochin Hos-
pital Paris, Paris (S.P.); INSERM Unité 724, 
University Hospital of Nancy, Vandoeuvre-
les-Nancy (J.-P.B.); and St. Joseph Hospi-
tal, Marseille (M.B.) — all in France; J.W. 
Goethe University Hospital, Frankfurt 
(N.F., S.Z.); and University Hospital of 
Cologne, Cologne (T.G.) — both in Ger-
many; Royal Free Hospital, London (G.D.); 
Medical University of Vienna, Vienna 
(P.F.); and Vertex Pharmaceuticals, Cam-
bridge, MA (S. Gharakhanian, L.B., L.M., 
S. George, T.K., A.K., R.S.K., J.A.). Address 
reprint requests to Dr. Pawlotsky at the 
Department of Virology, Hôpital Henri 
Mondor, 51 Ave. du Maréchal de Lattre 
de Tassigny, 94010 Créteil, France, or at 
jean-michel.pawlotsky@hmn.aphp.fr.
Drs. Hézode and Forestier contributed 
equally to this article.
*Members of the Protease Inhibition for 
Viral Evaluation 2 (PROVE2) study team 
are listed in the Appendix. 
N Engl J Med 2009;360:1839-50.
Copyright © 2009 Massachusetts Medical Society.
A BS TR AC T
Background
In patients with chronic infection with hepatitis C virus (HCV) genotype 1, treatment 
with peginterferon alfa and ribavirin for 48 weeks results in rates of sustained viro-
logic response of 40 to 50%. Telaprevir is a specific inhibitor of the HCV serine pro-
tease and could be of value in HCV treatment.
Methods
A total of 334 patients who had chronic infection with HCV genotype 1 and had not 
been treated previously were randomly assigned to receive one of four treatments 
involving various combinations of telaprevir (1250 mg on day 1, then 750 mg every 
8 hours), peginterferon alfa-2a (180 μg weekly), and ribavirin (dose according to 
body weight). The T12PR24 group (81 patients) received telaprevir, peginterferon 
alfa-2a, and ribavirin for 12 weeks, followed by peginterferon alfa-2a and ribavirin 
for 12 more weeks. The T12PR12 group (82 patients) received telaprevir, peginterferon 
alfa-2a, and ribavirin for 12 weeks. The T12P12 group (78 patients) received telapre-
vir and peginterferon alfa-2a without ribavirin for 12 weeks. The PR48 (control) group 
(82 patients) received peginterferon alfa-2a and ribavirin for 48 weeks. The primary 
end point, a sustained virologic response (an undetectable HCV RNA level 24 weeks 
after the end of therapy), was compared between the control group and the combined 
T12P12 and T12PR12 groups.
Results
The rate of sustained virologic response for the T12PR12 and T12P12 groups com-
bined was 48% (77 of 160 patients), as compared with 46% (38 of 82) in the PR48 
(control) group (P = 0.89). The rate was 60% (49 of 82 patients) in the T12PR12 group 
(P = 0.12 for the comparison with the PR48 group), as compared with 36% (28 of 78 
patients) in the T12P12 group (P = 0.003; P = 0.20 for the comparison with the PR48 
group). The rate was significantly higher in the T12PR24 group (69% [56 of 81 pa-
tients]) than in the PR48 group (P = 0.004). The adverse events with increased fre-
quency in the telaprevir-based groups were pruritus, rash, and anemia.
Conclusions
In this phase 2 study of patients infected with HCV genotype 1 who had not been 
treated previously, one of the three telaprevir groups had a significantly higher rate 
of sustained virologic response than that with standard therapy. Response rates were 
lowest with the regimen that did not include ribavirin. (ClinicalTrials.gov number, 
NCT00372385.)
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Hepatitis C virus (HCV) is the most common infectious cause of chronic liver disease in Europe and the United States. 
Chronic hepatitis C may result in life-threatening 
complications, including cirrhosis and hepatocel-
lular carcinoma. Antiviral therapy may result in a 
sustained virologic response, characterized by an 
undetectable HCV RNA level 24 weeks after the 
end of therapy, which correlates with a long-term 
clinical benefit. In patients infected with HCV gen-
otype 1, the most common genotype worldwide, 
the standard combination of peginterferon alfa 
and ribavirin for 48 weeks results in rates of sus-
tained virologic response of only 40 to 50%.1-3
A number of new therapeutic approaches are 
being assessed.4 The nonstructural 3/4A (NS3/4A) 
serine protease processes the HCV polyprotein to 
generate mature viral proteins. Direct protease in-
hibition emerged as a promising target for thera-
py when a reduction in viral replication of several 
log10 units was shown after 2 days of administra-
tion of an NS3/4A protease inhibitor.5
Telaprevir is a reversible, selective, orally bio-
available inhibitor of the HCV NS3/4A serine pro-
tease.6 Telaprevir monotherapy for 14 days induced 
a median decline of more than 4.4 log10 units in 
the plasma HCV RNA level in patients with chron-
ic HCV genotype 1 infection.7 In an early study, all 
12 patients with HCV genotype 1 who were receiv-
ing telaprevir with peginterferon and ribavirin for 
28 days had undetectable HCV RNA levels at the 
end of the therapy with these three study drugs.8
The Protease Inhibition for Viral Evaluation 2 
(PROVE2) trial was a multicenter, randomized, 
partially double-blind, placebo-controlled phase 2b 
trial conducted in Europe to assess the efficacy 
and adverse event profile of various regimens com-
bining telaprevir with peginterferon alfa-2a, with 
or without ribavirin, as compared with peginter-
feron alfa-2a and ribavirin alone, in patients in-
fected with HCV genotype 1 who had not been 
treated previously.
Me thods
Patients
Patients were enrolled at 28 centers in France, Ger-
many, the United Kingdom, and Austria between 
August 2, 2006, and January 17, 2007. Eligibility 
criteria included no previous treatment for HCV in-
fection, an age of 18 to 65 years, chronic HCV 
genotype 1 infection with detectable plasma HCV 
RNA levels, and no histologic evidence of cirrho-
sis within 2 years before study day 1.
The protocol and informed-consent form were 
approved by appropriate ethics committees at all 
study centers, in accordance with national proce-
dures. All patients provided written informed con-
sent before participating in the study. The study 
was conducted in accordance with the Declaration 
of Helsinki, Good Clinical Practice guidelines, and 
local laws and regulations.
Study Design
This was a phase 2b, randomized, partially double-
blind, placebo-controlled trial. Eligible patients 
were stratified on the basis of self-reported race 
or ethnic group (black or other) and baseline 
weight (>75 kg vs. ≤75 kg). Patients were random-
ly assigned to one of four treatment groups: the 
T12PR24 group, which received telaprevir (VX-950, 
Vertex Pharmaceuticals), peginterferon alfa-2a 
(Pegasys, Roche), and ribavirin (Copegus, Roche) 
for 12 weeks, followed by peginterferon alfa-2a and 
ribavirin for 12 more weeks; the T12PR12 group, 
which received telaprevir, peginterferon alfa-2a, 
and ribavirin for 12 weeks; the T12P12 group, 
which received telaprevir and peginterferon alfa-2a, 
without ribavirin, for 12 weeks; and the PR48 (con-
trol) group, which received placebo, peginterferon 
alfa-2a, and ribavirin for 12 weeks, followed by 
peginterferon alfa-2a and ribavirin for 36 more 
weeks. Randomization was performed through a 
central telephone-based system, in a 1:1:1:1 ratio 
(with randomization blocks of 4). In the PR48 
group, as in clinical practice,9 if there was a de-
cline of 2 log10 units in the plasma HCV RNA level 
at week 12 and the HCV RNA level was undetect-
able at week 24, treatment was continued; if not, 
treatment was stopped, since the chance of clear-
ing the infection was extremely low.10,11
Telaprevir was given as a single dose of 1250 
mg on study day 1, followed by a dose of 750 mg 
every 8 hours; peginterferon alfa-2a was given sub-
cutaneously at a dose of 180 μg per week; ribavirin 
was given orally at a dose of 1000 mg per day (for 
body weight <75 kg) or 1200 mg per day (for body 
weight ≥75 kg). Treatment of the PR48, T12PR12, 
and T12PR24 groups was double-blinded through 
week 10. Treatment of the T12P12 group was not 
blinded, because the absence of ribavirin would 
result in discernable hematologic effects. Patients 
in the T12PR24, T12PR12, and T12P12 groups 
were required to have undetectable HCV RNA lev-
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els at the last study visit before the planned end 
of treatment (i.e., at week 10 for the T12PR12 and 
T12P12 groups and at week 20 for the T12PR24 
group). If patients had detectable HCV RNA levels 
at this visit, they were to continue to receive peg-
interferon alfa-2a and ribavirin through treatment 
week 48. Since the intention was to assess the ef-
ficacy of shorter treatment durations, these pa-
tients were considered to have treatment failure in 
the analysis of a sustained virologic response.
The study sponsor and the academic principal 
investigators were responsible for study design and 
protocol development. The manuscript was draft-
ed by the principal academic authors with input 
from the publication committee (consisting of four 
academic authors). All authors had access to the 
data and assume responsibility for the accuracy 
and completeness of the data reported.
Efficacy Assessments
Plasma HCV RNA levels were measured with the 
use of the COBAS TaqMan HCV assay, version 1.0 
(Roche Molecular Systems), with a lower limit of 
quantification of 30 IU per milliliter and a lower 
limit of detection of 10 IU per milliliter. HCV RNA 
assessments were performed at the screening visit, 
at days 1, 4, and 8, and at weeks 2, 3, 4, 6, 8, 10, 
and 12; additional assessments occurred at weeks 
16, 20, and 24 in the T12PR24 and PR48 groups 
and at weeks 28, 36, and 48 in the PR48 group. 
All patients had a follow-up visit 2 weeks after 
completion of the study treatment. In patients in 
the three telaprevir-based groups who had com-
pleted all treatment (ending at week 12 or week 
24), HCV RNA levels were also measured 1, 2, 4, 
8, 12, 24, 36, and 48 weeks after completion of 
the study treatment.
Viral breakthrough during therapy was defined 
as an increase of more than 1 log10 IU per milli-
liter from the lowest HCV RNA level or as an HCV 
RNA level above 100 IU per milliliter in patients 
with previously undetectable HCV RNA. Relapse 
was defined as a detectable HCV RNA level dur-
ing the 24-week post-treatment period in patients 
who had undetectable HCV RNA at the end of 
treatment.
Safety Assessments
Safety assessments included physical examina-
tions, recording of adverse events, and serum 
chemical and hematologic evaluations at all study 
visits, and electrocardiography at the start and end 
of the treatment period. The original protocol was 
amended in January 2007 to add specific evalua-
tions for grade 3 or 4 rashes, including pharmaco-
kinetic analysis and HLA typing of blood samples.
Stepwise temporary reductions or short inter-
ruptions of ribavirin or peginterferon alfa-2a ther-
apy were permitted, to manage adverse events or 
laboratory abnormalities. Dose reduction or inter-
ruption of telaprevir was not allowed. The use of 
granulocyte colony-stimulating factor and eryth-
ropoietin was not allowed during the initial 12 
weeks of study treatment.
Statistical Analysis
The main efficacy measure was the proportion of 
patients who had a sustained virologic response: 
an HCV RNA level that was undetectable (<10 IU 
per milliliter) 24 weeks after the completion of 
study treatment. The analysis included all patients 
who had undergone randomization and had re-
ceived at least one dose of any study drug. The 
planned primary analysis was the comparison of 
the PR48 group with the T12PR12 group and the 
T12P12 group (which did not receive ribavirin) 
combined, and the planned secondary analysis was 
a comparison of each of the three telaprevir-based 
groups with the PR48 group. Assuming rates of 
sustained virologic response of 50% in the PR48 
group and 70% in the combined T12PR12 and 
T12P12 groups, we calculated that with 80 patients 
who could be evaluated in the PR48 group and 160 
who could be evaluated in the combined groups, 
the study would have a statistical power of at least 
80% to show a significant difference.
Five planned interim analyses were conducted 
by the sponsor, Vertex Pharmaceuticals, to monitor 
safety and assess antiviral efficacy during the treat-
ment period. Each interim analysis included de-
scriptive analyses of safety data (adverse events and 
laboratory data) and HCV RNA results. There were 
no stopping rules or a priori plans for changes to 
the study conduct on the basis of interim analyses.
After the third interim analysis, it became ap-
parent that the T12P12 group did not have a re-
sponse during the treatment period that was simi-
lar to the response of the T12PR12 group, and the 
statistical-analysis plan was revised by the sponsor 
to remove the originally planned primary analy-
sis. The original secondary analysis, a comparison 
of the sustained virologic response in each of the 
three telaprevir-based groups with the response 
in the PR48 group, became the primary analysis.
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Results of the fourth interim analysis (per-
formed after all patients had reached the end of 
the treatment period and data on sustained viro-
logic response were available for the T12PR24 
group) and fifth interim analysis (conducted when 
the PR48 group was still undergoing follow-up but 
data on the post-treatment responses for the three 
telaprevir groups were available) were made avail-
able to the investigators and presented at scientific 
meetings. Because it is not clear how to adjust the 
interpretation of the analyses for these unplanned 
changes and multiple examinations of the data, 
the results are reported as originally planned.
Treatment assignments were unblinded at week 
10 for all patients; therefore, there was no data 
and safety monitoring board. Safety of the patients 
was monitored by investigators and three study 
medical monitors, who reviewed all safety events, 
and by means of a review of adverse-event data 
during the interim analyses.
The comparisons between groups were per-
formed with the use of Fisher’s exact test. All re-
ported P values are two-sided and have not been 
adjusted for multiple testing. A prespecified multi-
variate analysis to evaluate the possible relation-
ship between a sustained virologic response and 
baseline variables (age, weight and body-mass in-
dex, and baseline HCV RNA level) was performed 
by means of a logistic-regression model with a 
sustained virologic response as the dependent vari-
able. The following factors were added post hoc 
and were also explored in the model: sex, HCV 
genotype 1 subtype (1a vs. 1b), and alanine ami-
notransferase and fasting glucose levels at base-
line. Variables that had a weak association (P>0.20) 
with a sustained virologic response in the initial 
logistic-regression model were excluded from the 
final model.
R esult s
Characteristics of the Patients
Of 388 patients screened, 334 were randomly as-
signed to a treatment group and 323 received study 
medication (Fig. 1). The characteristics of the treat-
ment groups were similar at baseline (Table 1).
Virologic Responses during the Treatment 
Period
Table 2 shows the proportion of patients with 
undetectable HCV RNA (<10 IU per milliliter) at 
weeks 4, 12, and 24 during the treatment period 
as well as 24 weeks after completion of planned 
treatment (the time of assessment for a sustained 
virologic response) in the four groups. The me-
dian time to an undetectable HCV RNA level was 
113 days (range, 15 to 337) in the PR48 group, 28 
days (range, 8 to 172) in the T12PR24 group, 22 
days (range, 4 to 85) in the T12PR12 group, and 
29 days (range, 4 to 86) in the T12P12 group. Fig-
ure 2 shows the mean change in HCV RNA levels 
during the first 12 weeks of treatment.
The proportions of patients who had undetect-
able HCV RNA levels at weeks 4 and 12 were sig-
nificantly higher in all telaprevir-based groups 
than in the PR48 group. At week 4, levels were 
undetectable in 69% of patients in the T12PR24 
group, 80% in the T12PR12 group, and 50% in 
the T12P12 group (vs. 13% in the PR48 group, 
P<0.001 for each comparison). At week 12, lev-
els were undetectable in 73% of patients in the 
T12PR24 group (vs. 43% in the PR48 group, 
P<0.001), 80% in the T12PR12 group (P<0.001), 
and 62% in the T12P12 group (P = 0.02). At the end 
of treatment — i.e., at week 24 in the T12PR24 
group, week 12 in the T12PR12 and T12P12 
groups, and week 48 in the PR48 group — the 
proportions of patients with undetectable HCV 
RNA levels were higher in both groups receiving 
Figure 1 (facing page). Enrollment and Follow-up 
among the Study Patients.
The reasons for the exclusion of the 54 patients were 
as follows: 29 did not meet the eligibility criteria  
(2 were not between 18 and 65 years of age, 2 had con-
current medical conditions, 6 had cirrhosis or another 
hepatic finding on biopsy, 8 had an HCV genotype oth-
er than 1, and 11 did not meet other criteria), 10 pa-
tients withdrew consent after starting the screening 
process, and 15 were excluded or the screening failed 
because of unknown reasons. Two patients underwent 
randomization twice (and were thus assigned two ran-
domization numbers) in error. Of the 334 patients 
(332, in actuality) who underwent randomization,  
11 (9, in actuality) did not receive any study drug: 5 pa-
tients withdrew consent between the time of random-
ization (5 to 7 days before the start of dosing) and day 
1, 2 were withdrawn by the investigators (1 at the dis-
cretion of the investigator and 1 for noncompliance 
with study requirements), 1 was lost to follow-up, and 
1 had cirrhosis but was randomized and then with-
drawn. The protocol-defined stopping rule (stating that 
patients must have had a drop of 2 log10 units in the 
HCV RNA level, as compared with the baseline level,  
at week 12 of treatment and an undetectable HCV RNA 
level at week 24 of treatment to continue to receive the 
study drugs) was applicable only to the PR48 group.
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all three study drugs (70% in the T12PR24 group 
and 80% in the T12PR12 group) and in the T12P12 
group (62%) than in the PR48 group (55%).
Sustained Virologic Response
A sustained virologic response, defined as an un-
detectable HCV RNA 24 weeks after completion 
of therapy, was the primary end point. In the three 
telaprevir-based groups, 19 patients (14 in the 
T12P12 group) had detectable HCV RNA at the last 
study visit before the planned end of treatment 
and were therefore assigned to complete a total of 
48 weeks of peginterferon alfa-2a and ribavirin, 
according to the protocol. Seven patients (all in the 
T12P12 group) completed this treatment; three of 
the seven had a sustained virologic response but 
were counted as having treatment failure in the 
analysis of the rate of sustained virologic response.
The rate of sustained virologic response for the 
PR48 group was 46% (38 of 82 patients). Accord-
ing to the originally planned primary analysis, the 
rate of sustained virologic response for the com-
bined T12P12 and T12PR12 groups was 48% (77 
of 160, P = 0.89 for the comparison with the PR48 
group).
In the T12PR24 group, a sustained virologic 
Table 1. Baseline Characteristics of the Study Patients, According to Treatment Group.*
Characteristic T12PR24 (N = 81) T12PR12 (N = 82) T12P12 (N = 78) PR48 (N = 82)
Years of age — median (range) 46 (19–65) 44 (22–65) 45 (20–64) 45 (18–64)
BMI — median (range)† 24 (17–35) 23 (17–32) 24 (18–41) 24 (17–35)
Male sex — no. (%) 54 (67) 49 (60) 43 (55) 46 (56)
Race or ethnic group — no. (%)‡
White 75 (93) 76 (93) 77 (99) 76 (93)
Black 1 (1) 2 (2) 1 (1) 2 (2)
Asian 3 (4) 2 (2) 0 4 (5)
Hispanic 1 (1) 1 (1) 0 0
Other 1 (1) 1 (1) 0 0
HCV RNA — log10 IU/ml 6.5±0.6 6.4±0.6 6.3±0.6 6.4±0.6
HCV RNA ≥800,000 IU/ml — no. (%) 73 (90) 67 (82) 63 (81) 68 (83)
Fibrosis on previous liver biopsy — no. (%)
None or minimal 35 (43) 30 (37) 31 (40) 28 (34)
Portal 37 (46) 46 (56) 43 (55) 46 (56)
Bridging  9 (11) 6 (7) 3 (4)  8 (10)
Cirrhosis§ — — 1 (1) —
ALT, IU/ml — median (range) 56 (18–277) 50 (15–259) 58 (18–303) 55 (20–315)
HCV genotype 1 subtype — no. (%)¶
1a 31 (38) 37 (45) 40 (51) 35 (43)
1b 50 (62) 45 (55) 38 (49) 45 (55)
Indeterminate 0 0 0 2 (2)
* Plus–minus values are means ±SD. Patients were randomly assigned to receive one of four treatments involving vari-
ous combinations of telaprevir (1250 mg on day 1, then 750 mg every 8 hours), peginterferon alfa-2a (180 μg weekly), 
and ribavirin (dose according to body weight). The T12PR24 group received telaprevir, peginterferon alfa-2a, and ribavi-
rin for 12 weeks, followed by peginterferon alfa-2a and ribavirin for 12 more weeks. The T12PR12 group received tel-
aprevir, peginterferon alfa-2a, and ribavirin for 12 weeks. The T12P12 group received telaprevir and peginterferon alfa-
2a without ribavirin for 12 weeks. The PR48 (control) group received peginterferon alfa-2a and ribavirin for 48 weeks.
There were no significant differences between the control group and any of the three telaprevir-based groups. ALT de-
notes alanine aminotransferase, and HCV hepatitis C virus. 
† The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.
‡ Race or ethnic group was self-reported. Percentages do not total 100 because of rounding.
§ Patients with cirrhosis on previous biopsy were excluded from the study; however, one such patient was enrolled in er-
ror by a site investigator.
¶ HCV genotype and subtype were determined through sequence analysis of the coding region of the nonstructural 3 
protease, performed as part of resistance studies.
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response was achieved in 47 of the 61 patients who 
completed the assigned treatment and in 9 of the 
20 patients who discontinued the study treatment 
before week 24, for an overall rate of 69% (56 of 
81 patients), which was significantly higher than 
that in the PR48 group (P = 0.004). The rate of sus-
tained virologic response was not significantly 
higher in the T12PR12 group or the T12P12 group 
than in the PR48 group. In the T12PR12 group, 
there was a sustained virologic response in 46 of 
the 72 patients who completed treatment and in 
3 of the 10 who discontinued treatment, for an 
overall rate of 60% (49 of 82 patients, P = 0.12 for 
the comparison with the PR48 group). In the 
group not receiving ribavirin (the T12P12 group), 
a sustained virologic response was achieved in 24 
of the 70 patients who completed treatment and 
in 4 of the 8 who discontinued treatment, for an 
overall rate of 36% (28 of 78 patients, P = 0.20 for 
the comparison with the PR48 group). The differ-
ence between the rates in the T12PR12 group and 
the T12P12 group was significant (P = 0.003).
Viral Breakthrough and Relapse
By week 12, a viral breakthrough had  been ob-
served in 1 of 82 patients (1%) in the PR48 group, 
19 of 78 (24%) in the T12P12 group, 1 of 82 (1%) 
in the T12PR12 group, and 4 of 81 (5%) in the 
T12PR24 group. Additional viral breakthroughs 
occurred in 1 of the 81 patients in the T12PR24 
group, after the completion of telaprevir, and in 
3 of the 82 patients in the PR48 group between 
weeks 12 and 48.
Relapse (defined as a detectable HCV RNA level 
during the 24-week post-treatment period in pa-
tients who had undetectable HCV RNA at the end 
of the treatment period) occurred in 8 of 57 pa-
tients (14%) in the T12PR24 group, 19 of 63 (30%) 
in the T12PR12 group, 22 of 46 (48%) in the 
T12P12 group, and 10 of 45 (22%) in the PR48 
group. In the T12PR24 group, the relapse rate 
among those who had undetectable HCV RNA at 
weeks 4 and 12 was 7% (3 of 45 patients).
In the T12PR24, T12PR12, and T12P12 groups, 
of the 133 patients with a sustained virologic re-
sponse, 118 returned for follow-up visits through 
48 weeks after the completion of treatment. Two 
of the 133 patients had a late relapse: 1 in the 
T12PR24 group had discontinued treatment on 
day 65 and had an HCV RNA level that became 
detectable 48 weeks after the end of treatment; 
the other, in the T12P12 group, had discontinued 
treatment on day 60 and had a detectable HCV 
RNA level 36 weeks after the end of treatment. 
In both patients, viral sequence analysis confirmed 
the recurrence of the original infection.
Analysis of the full-length NS3 protease se-
quence was carried out in patients with a break-
through and in those who had a relapse after 
completion of telaprevir therapy. HCV virus that 
had low-level resistance to telaprevir was found at 
baseline in 1% of patients. Among the 22 patients 
Table 2. Undetectable HCV RNA Levels during and after Treatment, According to Treatment Group.*
Week Undetectable Viral RNA
T12PR24 
(N = 81)
P Value,  
vs. PR48
T12PR12 
(N = 82)
P Value,  
vs. PR48
T12P12 
(N = 78)
P Value, 
vs. PR48
T12PR12 and 
T12P12 
(N = 160)
P Value,  
vs. PR48
PR48  
(N = 82)
Treatment week — no. (%)
4 56 (69) <0.001 66 (80) <0.001 39 (50) <0.001 105 (66) <0.001 11 (13)
12 59 (73) <0.001 66 (80) <0.001 48 (62) 0.02 114 (71) <0.001 35 (43)
24 57 (70) NA NA NA 48 (59)
48 NA NA NA NA 45 (55)
Follow-up week 24, when  
SVR was assessed†
No. (%) 56 (69) 0.004 49 (60) 0.12 28 (36) 0.20 77 (48) 0.89 38 (46)
95% CI‡ 58–79 48–70 25–47 40–56 36–58
* An undetectable level was defined as less than 10 IU per milliliter, according to the COBAS TaqMan assay (Roche Molecular Systems). NA 
denotes not applicable. The PR48 group was the control group.
† The rates of sustained virologic response (SVR) differed significantly between the T12PR12 group and the T12P12 group (P = 0.003).
‡ The 95% confidence intervals for the difference between the PR48 group and the telaprevir-based groups are as follows: T12PR24, 0.08 to 
0.38; T12PR12, −0.02 to 0.29; T12P12, −0.26 to 0.049; and T12PR12 and T12P12 combined, −0.12 to 0.15.
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who had a viral breakthrough during the 12 weeks 
of telaprevir administration and had a viral RNA 
level above the limit of detection of the sequencing 
assay, wild-type virus was found in 1 (5%), variants 
with low-level resistance in 9 (41%), and variants 
with high-level resistance in 12 (55%) (Table 3). 
Among the 42 patients who had a relapse after 
completion of treatment with telaprevir and had 
a viral RNA level above the limit of detection of 
the sequencing assay, wild-type virus was found 
in 2 (5%), low-level resistant variants in 33 (79%) 
and high-level resistant variants in 7 (17%). In 
some patients who did not receive ribavirin, com-
plex changes in sequence were seen during the 
study.
Independent Predictors of Sustained 
Virologic Response
The association between a sustained virologic re-
sponse and independent variables was explored 
with the use of a logistic-regression model. Treat-
ment group and baseline HCV RNA level were the 
only two variables significantly associated with a 
sustained virologic response (P<0.001) (Table 1 in 
the Supplementary Appendix, available with the 
full text of this article at NEJM.org).
Safety
Table 4 lists the principal adverse events reported 
in each group. Pruritus and rash were more fre-
quent in the telaprevir groups than in the control 
group. Pruritus occurred in 51% of patients (41 of 
81) in the T12PR24 group, 63% (52 of 82) in the 
T12PR12 group, and 59% (46 of 78) in the T12P12 
group, as compared with 35% (29 of 82) in the 
PR48 group. The incidence of rash was 49% (40 
of 81 patients) in the T12PR24 group, 44% (36 of 
82) in the T12PR12 group, and 47% (37 of 78) in 
the T12P12 group, as compared with 35% (29 of 
82) in the PR48 group. The rashes in patients in 
the telaprevir-based groups were generally macu-
lopapular and were clinically similar to those ob-
served in drug reactions. The median time to the 
appearance of a rash of any severity in the telapre-
vir-based groups was 9 to 12 days. Severe (grade 3) 
rash was found in 7% of patients (6 of 81) in the 
T12PR24 group, 6% (5 of 82) in the T12PR12 group, 
and 3% (2 of 78) in the T12P12 group, but was 
not seen in the PR48 group (Table 4). There were 
no grade 4 rashes reported. Twelve of the 163 pa-
tients (7%) in the combined T12PR24 and T12PR12 
groups discontinued treatment because of rash.
Telaprevir administration also affected hemo-
globin levels during the treatment period. During 
the first 12 weeks of treatment, the median de-
crease in the baseline hemoglobin level was 3.0 g 
per deciliter in the PR48 group, 3.1 g per deciliter 
in the T12P12 group, and 3.6 and 3.9 g per deci-
liter in the T12PR24 and T12PR12 groups, respec-
tively.
Other adverse events were similar in type and 
frequency in the telaprevir-based groups and the 
control group. Twenty-eight of the 241 patients 
(12%) in the telaprevir-based groups discontinued 
the study treatment because of adverse events, 
including 18 patients who did so before week 12 
(i.e., during the period of telaprevir administra-
tion), as compared with 6 of 82 patients (7%) in 
the control group.
Discussion
In this phase 2 study of patients infected with 
HCV genotype 1 who had not been treated previ-
ously, one of the three telaprevir-containing regi-
mens tested — treatment with telaprevir for 12 
weeks and peginterferon alfa-2a and ribavirin for 
24 weeks (T12PR24) — resulted in a significantly 
higher rate, by approximately 20 percentage points, 
of sustained virologic response than was found 
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with the standard therapy of 48 weeks of peginter-
feron alfa-2a and ribavirin (PR48). These data, to-
gether with those from a similar phase 2 study per-
formed in the United States (PROVE1, described 
elsewhere in this issue of the Journal),12 support 
the performance of a larger, phase 3 trial of tel-
aprevir in combination with peginterferon alfa-2a 
and ribavirin.
However, several questions remain unanswered. 
Patients with cirrhosis were not evaluated. Dura-
tions of triple-combination therapies with peginter-
feron alfa, ribavirin, and telaprevir that differ from 
the durations tested in PROVE2 will require fur-
ther investigation, as will the criteria for exten-
sion of peginterferon alfa and ribavirin therapy. 
Further investigation will shed light on the useful-
ness of tailoring therapy on the basis of the kinet-
ics of the early viral response.
Our results show the necessity of administer-
ing ribavirin in combination with peginterferon 
alfa and telaprevir. Ribavirin will most likely be 
required in combination with the use of other spe-
cific HCV inhibitors and peginterferon alfa to 
achieve the high rates of sustained virologic re-
sponse seen in our study. Among patients receiv-
ing telaprevir-based regimens, the addition of riba-
virin increased the sustained virologic response 
rates by preventing relapse and the emergence of 
both low-level and high-level telaprevir resistance. 
In spite of its moderate, transient antiviral effect 
on HCV replication when administered as mono-
therapy,13 ribavirin has been shown to prevent viral 
breakthrough during, and relapse after, the treat-
ment period by significantly accelerating the sec-
ond slope of viral-RNA decrease in patients who 
have a response to the antiviral effect of peginter-
feron alfa.14 The modes of action of ribavirin re-
main under debate.15-19 Our study results are con-
sistent with the notion that ribavirin does not act 
by directly inhibiting HCV replication, since it can-
not be replaced by a potent HCV inhibitor in com-
bination with peginterferon alfa-2a.
Both rash and pruritus were frequently re-
ported in this study, but they did not always occur 
in combination. Severe rash occurred in approxi-
mately 5% of patients treated with telaprevir. Both 
rash and pruritus regressed after withdrawal of 
telaprevir and administration of appropriate ther-
apy, including topical treatments for symptoms 
and corticosteroids (in some cases, systemic cor-
ticosteroids). Patients receiving telaprevir should 
be clinically monitored for dermatologic reactions 
and treated appropriately. The optimal manage-
ment of rash and its effect on treatment adherence 
Table 3. Incidence of Amino Acid Substitutions in Patients Who Had Viral Breakthrough or Relapse.*
Viral Activity Total No.
No. with Viral 
Level below 
LOD
No. with Wild-
Type Variant Low-Level Resistance High-Level Resistance
V36A/M T54A R155K/T A156S Various†
V36M and 
R155K A156T
number of patients
T12PR24
Breakthrough 4 3 1
Relapse 8 1 2 1 1 3
T12PR12
Breakthrough 1 1
Relapse 19 3 1 2 4 3 3 1 2
T12P12
Breakthrough 19 2 1 4 1 3 6 2
Relapse 22 4 2 4 6 2 2 2
* Breakthrough was defined as viral breakthrough during the 12 weeks of telaprevir administration. Relapse was defined as a detectable HCV 
RNA level during the 24-week post-treatment period in patients who had undetectable HCV RNA at the time of completion of the assigned 
treatment. The limit of detection (LOD) was an HCV RNA level of 1000 IU per milliliter, as measured with the use of the nonstructural 3 
serine protease sequencing assay.
† The specific combinations of substitutions were V36V/M and R155R/K for the one patient in the T12PR12 group who had a relapse; V36V/A 
and A156S/T in one patient, T54T/A and A156A/S in the second, and T54T/A, R155R/K, and A156A/S/T in the third who had a break-
through in the T12P12 group; and V36V/M, R155R/K, and V36V/A in one patient and V36V/A and T54T/A in the other who had a relapse in 
the T12P12 group.
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Table 4. Incidence of Adverse Events and Severe (Grade 3) Adverse Events between Baseline and Week 48, According to Treatment Group.*
System Organ Class 
 or Preferred Term Adverse Events Severe Adverse Events
T12PR24 
(N = 81)
T12PR12 
(N = 82)
T12P12 
(N = 78)
PR48 
 (N = 82)
T12PR24 
(N = 81)
T12PR12 
(N = 82)
T12P12 
(N = 78)
PR48 
 (N = 82)
number of patients (percent)
Any 80 (99) 82 (100) 78 (100) 81 (99) 13 (16) 17 (21) 10 (13) 13 (16)
General disorder or administra-
tion-site condition
72 (89) 75 (91) 65 (83) 73 (89) 1 (1) 4 (5) 2 (3) 2 (2)
Asthenia 37 (46) 43 (52) 30 (38) 26 (32) 1 (1) 3 (4) 1 (1) 1 (1)
Influenza-like illness 32 (40) 32 (39) 28 (36) 43 (52) 0 0 0 0
Fatigue 21 (26) 23 (28) 26 (33) 30 (37) 0 1 (1) 0 0
Pyrexia 14 (17) 15 (18) 15 (19) 19 (23) 0 1 (1) 0 0
Skin or subcutaneous-tissue  
disorder
74 (91) 78 (95) 68 (87) 60 (73) 7 (9) 7 (9) 2 (3) 0
Pruritus 41 (51) 52 (63) 46 (59) 29 (35) 2 (2) 1 (1) 1 (1) 0
Dry skin 21 (26) 21 (26) 22 (28) 29 (35) 0 0 0 0
Any rash 40 (49) 36 (44) 37 (47) 29 (35) 6 (7) 5 (6) 2 (3) 0
Alopecia 15 (19) 3 (4) 11 (14) 17 (21) 0 0 0 0
Gastrointestinal disorder 62 (77) 68 (83) 56 (72) 69 (84) 2 (2) 1 (1) 1 (1) 0
Nausea 39 (48) 39 (48) 24 (31) 33 (40) 1 (1) 0 0 0
Diarrhea 20 (25) 26 (32) 20 (26) 23 (28) 0 0 0 0
Nervous system disorder 48 (59) 49 (60) 43 (55) 45 (55) 1 (1) 2 (2) 1 (1) 1 (1)
Headache 36 (44) 32 (39) 37 (47) 37 (45) 0 0 0 0
Psychiatric disorder 44 (54) 45 (55) 35 (45) 49 (60) 0 2 (2) 3 (4) 1 (1)
Insomnia 23 (28) 28 (34) 11 (14) 32 (39) 0 0 1 (1) 0
Depression 16 (20) 18 (22) 17 (22) 19 (23) 0 2 (2) 2 (3) 0
Respiratory, thoracic and medi-
astinal disorder 
39 (48) 44 (54) 27 (35) 39 (48) 3 (4) 0 0 0
Dyspnea 18 (22) 21 (26) 11 (14) 13 (16) 1 (1) 0 0 0
Cough 15 (19) 14 (17) 8 (10) 21 (26) 0 0 0 0
Musculoskeletal or connective-
tissue disorder
27 (33) 28 (34) 38 (49) 44 (54) 0 0 1 (1) 1 (1)
Myalgia 11 (14) 12 (15) 12 (15) 17 (21) 0 0 0 0
Arthralgia 8 (10) 8 (10) 20 (26) 14 (17) 0 0 0 1 (1)
Blood or lymphatic system  
disorder
25 (31) 23 (28) 15 (19) 26 (32) 3 (4) 5 (6) 3 (4) 7 (9)
Anemia† 22 (27) 15 (18) 7 (9) 14 (17) 3 (4) 3 (4) 1 (1) 2 (2)
Metabolic or nutritional  
disorder
10 (12) 16 (20) 20 (26) 20 (24) 0 0 0 0
Decreased appetite 5 (6) 9 (11) 16 (21) 16 (20) 0 0 0 0
* The adverse events listed occurred in 20% or more of patients in any group, such that the number for the total system organ class may ex-
ceed the sum of the numbers for the preferred terms. The severe adverse events listed were all grade 3. The system organ classes and pre-
ferred terms are from the Medical Dictionary for Regulatory Activities, version 10. Bold text indicates an adverse event or serious adverse 
event for which the incidence in any telaprevir-based group was at least 10 percentage points higher than the incidence in the control group. 
Four adverse events (in three patients) were reported as grade 4 by site investigators: a life-threatening car accident and subsequent sple-
nectomy in one patient, paranoia in another, and anemia in the third. The PR48 group was the control group.
† Anemia, with regard to adverse events as listed here, was reported by the site investigators, with no requirement for a specific value or 
change in the hemoglobin level.
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and efficacy requires further investigation. De-
creased hemoglobin levels were also more fre-
quent among the patients receiving telaprevir than 
among those in the control group, though the con-
dition was not often a cause of treatment discon-
tinuation.
In conclusion, although a significant improve-
ment in sustained virologic response was not 
shown in association with two of the telaprevir 
regimens tested, 12 weeks of telaprevir combined 
with 24 weeks of peginterferon alfa-2a and riba-
virin resulted in significantly higher rates of sus-
tained virologic response than 48 weeks of peg-
interferon and ribavirin alone. This study therefore 
suggests that the use of telaprevir may improve the 
rate of sustained virologic response in patients 
with a chronic HCV genotype 1 infection. A drug-
induced rash necessitated that telaprevir be dis-
continued in some patients. Larger and longer 
studies are required to assess the efficacy and 
safety of telaprevir for HCV infection.
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